Medigen Vaccines SARS-CoV-2 qPCR Kit obtained CE Marking and Taiwan MOHW’s approval

On Apr. 30, 2020, Medigen Vaccine Biologics (MVC) announced its SARS-CoV-2 qPCR Kit complied with EU CE requirements, completed the EU declaration of conformity and obtained CE marking (IVD) on Apr. 24, 2020. In addition, MVC applied for specific medical devicesメ manufacturing in Taiwan.

Tags:


Source: Medigen Vaccine Biologics
Credit:

bioinnovatise accelerates scientific discovery by providing fast, reliable, and high-quality CDMO services for plasmid DNA and viral vector-based research.